Skip to main content
Top

Open Access 11-03-2025 | Dementia | Systematic Review

Medicine Optimisation and Deprescribing Intervention Outcomes for Older People with Dementia or Mild Cognitive Impairment: A Systematic Review

Authors: Nicola Andrews, Cindy Brooks, Michele Board, Simon Fraser, Sue Latter, Kirsty Aplin, Beth McCausland, Eloise Radcliffe, Jay Amin, Rosemary Lim, Ellen van Leeuwen, Kinda Ibrahim

Published in: Drugs & Aging

Login to get access

Abstract

Background

Polypharmacy is common amongst older people with dementia or mild cognitive impairment (MCI), increasing the risk of medication-related harm. Medicine optimisation and deprescribing to reduce polypharmacy is considered feasible, safe and can lead to improved health. However, for those living with dementia or MCI, this can be challenging. This systematic review aimed to summarise the evidence on the outcomes of medicine optimisation and deprescribing interventions for older people with dementia or MCI.

Methods

Literature was searched using CINAHL, Embase, Medline, PsychINFO, Web of Science and the Cochrane Library from database inception to January 2024. Papers reporting data specific to people with dementia or MCI from medicine optimisation and deprescribing interventional research studies of any design and in any setting were included. A narrative synthesis was conducted owing to heterogeneity of study designs and outcomes. Quality was assessed using the Mixed Methods Appraisal Tool.

Results

A total of 32 papers reporting on 28 studies were included, with samples ranging from 29 to 17,933 patients and a mean patient age ranging from 74 to 88 years. Of the studies, 60% were undertaken in long-term care settings. Involvement of patients and/or carers in interventions was limited. Papers were grouped as either incorporating a medication review component (n = 13), education component (n = 5) or both (n = 14). Studies primarily focussed on medication-related outcomes, generally showing a positive effect on decreasing the number and improving appropriateness of medications. Fewer papers reported clinical outcomes (behavioural and psychological symptoms of dementia, falls, quality of life and cognition) with mixed findings. A reduction or no change in mortality or hospital attendance demonstrated safety of the interventions in the few papers reporting these outcomes. The quality of the evidence was mixed.

Conclusions

Medicine optimisation and deprescribing interventions generally reduced the number and increased the appropriateness of medications, and although less frequently reported, these interventions seemed to be safe and showed an absence of worsening of clinical outcomes. This review highlights a need for further research, particularly in people with dementia or MCI living at home, with more focus on clinical outcomes and a greater involvement of patients and informal carers.

Protocol Registration

The protocol was published in the International Prospective Register of Systematic Reviews (PROSPERO) [Ref: CRD42023398139].
Appendix
Available only for authorised users
Literature
1.
go back to reference Clague F, Mercer SW, McLean G, Reynish E, Guthrie B. Comorbidity and polypharmacy in people with dementia: insights from a large, population-based cross-sectional analysis of primary care data. Age Ageing. 2017;46:33–9.PubMed Clague F, Mercer SW, McLean G, Reynish E, Guthrie B. Comorbidity and polypharmacy in people with dementia: insights from a large, population-based cross-sectional analysis of primary care data. Age Ageing. 2017;46:33–9.PubMed
3.
go back to reference Mueller C, Molokhia M, Perera G, Veronese N, Stubbs B, Shetty H, et al. Polypharmacy in people with dementia: associations with adverse health outcomes. Exp Gerontol. 2018;106:240–5.CrossRefPubMed Mueller C, Molokhia M, Perera G, Veronese N, Stubbs B, Shetty H, et al. Polypharmacy in people with dementia: associations with adverse health outcomes. Exp Gerontol. 2018;106:240–5.CrossRefPubMed
7.
11.
go back to reference Thompson W, Farrell B. Deprescribing: what is it and what does the evidence tell us? Can J Hosp Pharm. 2013;66:201–2.PubMedPubMedCentral Thompson W, Farrell B. Deprescribing: what is it and what does the evidence tell us? Can J Hosp Pharm. 2013;66:201–2.PubMedPubMedCentral
13.
go back to reference Iyer S, Naganathan V, McLachlan AJ, Le Couteur DG. Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging. 2008;25:1021–31.CrossRefPubMed Iyer S, Naganathan V, McLachlan AJ, Le Couteur DG. Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging. 2008;25:1021–31.CrossRefPubMed
19.
41.
go back to reference Weeks WB, Mishra MK, Curto D, Petersen CL, Cano P, Hswen Y, et al. Comparing three methods for reducing psychotropic use in older demented Spanish care home residents. J Am Geriatr Soc. 2019;67(7):1444–53.CrossRefPubMed Weeks WB, Mishra MK, Curto D, Petersen CL, Cano P, Hswen Y, et al. Comparing three methods for reducing psychotropic use in older demented Spanish care home residents. J Am Geriatr Soc. 2019;67(7):1444–53.CrossRefPubMed
42.
46.
go back to reference van der Spek K, Koopmans RTCM, Smalbrugge M, Nelissen-Vrancken MHJMG, Wetzels RB, Smeets CHW, et al. The effect of biannual medication reviews on the appropriateness of psychotropic drug use for neuropsychiatric symptoms in patients with dementia: a randomised controlled trial. Age Ageing. 2018. https://doi.org/10.1093/ageing/afy001.CrossRefPubMed van der Spek K, Koopmans RTCM, Smalbrugge M, Nelissen-Vrancken MHJMG, Wetzels RB, Smeets CHW, et al. The effect of biannual medication reviews on the appropriateness of psychotropic drug use for neuropsychiatric symptoms in patients with dementia: a randomised controlled trial. Age Ageing. 2018. https://​doi.​org/​10.​1093/​ageing/​afy001.CrossRefPubMed
50.
go back to reference Ballard C, Orrell M, Sun Y, Moniz-Cook E, Stafford J, Whitaker R, et al. Impact of antipsychotic review and non-pharmacological intervention on health-related quality of life in people with dementia living in care homes: WHELD-a factorial cluster randomised controlled trial. Int J Geriatr Psychiatry. 2017. https://doi.org/10.1002/gps.4572.CrossRefPubMed Ballard C, Orrell M, Sun Y, Moniz-Cook E, Stafford J, Whitaker R, et al. Impact of antipsychotic review and non-pharmacological intervention on health-related quality of life in people with dementia living in care homes: WHELD-a factorial cluster randomised controlled trial. Int J Geriatr Psychiatry. 2017. https://​doi.​org/​10.​1002/​gps.​4572.CrossRefPubMed
55.
go back to reference Ballard C, Orrell M, YongZhong S, Moniz-Cook E, Stafford J, Whittaker R, et al. Impact of antipsychotic review and nonpharmacological intervention on antipsychotic use, neuropsychiatric symptoms, and mortality in people with dementia living in nursing homes: a factorial cluster-randomized controlled trial by the Well-Being and Health for People with Dementia (WHELD) program. Am J Psychiatry. 2016. https://doi.org/10.1176/appi.ajp.2015.15010130.CrossRefPubMedPubMedCentral Ballard C, Orrell M, YongZhong S, Moniz-Cook E, Stafford J, Whittaker R, et al. Impact of antipsychotic review and nonpharmacological intervention on antipsychotic use, neuropsychiatric symptoms, and mortality in people with dementia living in nursing homes: a factorial cluster-randomized controlled trial by the Well-Being and Health for People with Dementia (WHELD) program. Am J Psychiatry. 2016. https://​doi.​org/​10.​1176/​appi.​ajp.​2015.​15010130.CrossRefPubMedPubMedCentral
60.
go back to reference Andrew MK, Purcell CA, Marshall EG, Varatharasan, Clarke B, Bowles SK. Polypharmacy and use of potentially inappropriate medications in long-term care facilities: does coordinated primary care make a difference? Int J Pharm Pract. 2018; https://doi.org/10.1111/ijpp.12397 Andrew MK, Purcell CA, Marshall EG, Varatharasan, Clarke B, Bowles SK. Polypharmacy and use of potentially inappropriate medications in long-term care facilities: does coordinated primary care make a difference? Int J Pharm Pract. 2018; https://​doi.​org/​10.​1111/​ijpp.​12397
65.
go back to reference 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers criteria (R) for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023; https://doi.org/10.1111/jgs.18372 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers criteria (R) for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023; https://​doi.​org/​10.​1111/​jgs.​18372
68.
go back to reference Prince M, Knapp M, Guerchet M, McCrone P, Prina M. Comas-Herrera M, et al. Dementia UK: update. Alzheimer’s Society; 2014. Prince M, Knapp M, Guerchet M, McCrone P, Prina M. Comas-Herrera M, et al. Dementia UK: update. Alzheimer’s Society; 2014.
75.
go back to reference Liu BM, Redston MR, Fujita K, Thillainadesan J, Gnjidic D, Hilmer S. The impact of deprescribing interventions on the Drug Burden Index and other outcomes: a systematic review. J Am Med Dir Assoc. 2024;25(7): 105021.CrossRefPubMed Liu BM, Redston MR, Fujita K, Thillainadesan J, Gnjidic D, Hilmer S. The impact of deprescribing interventions on the Drug Burden Index and other outcomes: a systematic review. J Am Med Dir Assoc. 2024;25(7): 105021.CrossRefPubMed
77.
go back to reference Banerjee S. The use of antipsychotic medication for people with dementia: time for action. Department of Health; 2009. Banerjee S. The use of antipsychotic medication for people with dementia: time for action. Department of Health; 2009.
Metadata
Title
Medicine Optimisation and Deprescribing Intervention Outcomes for Older People with Dementia or Mild Cognitive Impairment: A Systematic Review
Authors
Nicola Andrews
Cindy Brooks
Michele Board
Simon Fraser
Sue Latter
Kirsty Aplin
Beth McCausland
Eloise Radcliffe
Jay Amin
Rosemary Lim
Ellen van Leeuwen
Kinda Ibrahim
Publication date
11-03-2025
Publisher
Springer International Publishing
Published in
Drugs & Aging
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-025-01189-2

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now
Video